VSY Biotechnology to Announce First Clinical Experiences of AcrivaUD Trinova Pro C Pupil Adaptive® at ESCRS Congress

VSY Biotechnology GmbH, an innovation-driven company with progressive R&D activities in ophthalmology, is readying to share the first clinical experiences of  AcrivaUD Trinova Pro C Pupil Adaptive®, the first and only trifocal IOL that combines patented enhanced Sinusoidal Vision Technology (SVT®) with Pupil Adaptive Design at ESCRS Congress 2022 at the Milano Convention Centre in Milan, Italy.

The clinical results will be announced during a satellite symposium session on Sunday 18, September between 13:00-14:00 in Room Space 4. The moderator of the symposium will be Prof. Dr. Ike Ahmed, who will kick off the session with a question: “why rethinking diffraction?”. He will then share general information about the innovative IOL within the concept of the Golden Ratio in IOL technology.

Following the introduction, Prof. Dr. Gerd U. Auffarth from Germany will share optical quality results from the D.J. Apple Laboratory comparing the state-of-the-art presbyopia-correcting IOLs. The session will continue with Dr. Karsten Klabe, who will be revealing clinical results after bilateral implantation of the new patented trifocal IOL with enhanced Sinusoidal Vision Technology (SVT®) vs. PanOptix. The symposium will end with Dr. Ramon Ruiz Mesa’s speech regarding the initial clinical outcomes of the new IOL in Spain.

In addition, the annual Ophthalmology Star Awards (OSA) Ceremony will be held at the end of the symposium, and awards will be handed out to the winners, which are ranked based upon their scientific research’s usefulness for the clinical ophthalmologist, novelty, and readability of the paper.

After the satellite symposium, there is a 20-min breakout session planned at the VSY Biotechnology’s booth at B42 Hall 4 between 14:25-14:45. Prof. Dr. Oliver Findl, President of the ESCRS, Dr. Basak Bostanci, and Dr. Florian Kretz will have a quick discussion about hydrophilics or hydrophobics.

About AcrivaUD Trinova Pro C Pupil Adaptive®

AcrivaUD Trinova Pro C Pupil Adaptive® is the first and only trifocal lens with VSY Biotechnology’s Patented Enhanced Sinusoidal Vision Technology (SVT®) that combines with pupil adaptive design. Enhanced Sinusoidal Vision Technology that mimics a sine wave-like surface profile is designed to obtain the ideal optical performance.

AcrivaUD Trinova Pro C Pupil Adaptive® has the highest light transmission to the retina by 93% among all available trifocal IOLs and it is the nearest value to the crystalline lens, thanks to its step-less diffractive zones which improve contrast sensitivity.

AcrivaUD Trinova Pro C Pupil Adaptive® aims to reach “The Golden Ratio” in optical design, allowing the patient to achieve the highest level of visual quality not only in ideal conditions but also in challenging conditions in everyday life.

The new lens uses patented Sinusoidal Vision Technology (SVT®), a proprietary design that optimizes to distribute effective and efficient light energy into the near and intermediate distances while maintaining distance visual acuity due to minimized light loss in the diffraction orders provided by enhanced light distribution with patented Sinusoidal Vision Technology (SVT®).

AcrivaUD Trinova Pro C Pupil Adaptive® is available by +1.8D intermediate and +3.6D near addition dioptric powers in the IOL plane. The IOL easily adapts to today’s lifestyles from viewing road signs comfortably and clearly while driving at night safety, to viewing mobile devices and computer screens, to reading a book comfortably even in dim light providing high quality distance vision in a range of different light conditions. By increasing the visual quality of the patients to the highest level, it improves the quality of life and offers a "Golden Ratio" vision experience.